Study to Assess Maternal and Infant Outcomes Following Exposure to SPIKEVAX During Pregnancy
- Conditions
- Maternal OutcomesInfant OutcomesPregnancy
- Registration Number
- NCT06369272
- Lead Sponsor
- ModernaTX, Inc.
- Brief Summary
The primary objectives of this study are:
In infants of women exposed to SPIKEVAX during pregnancy, to assess:
* If exposure to SPIKEVAX during pregnancy is associated with an increased birth prevalence of major congenital malformations (MCMs).
* If exposure to SPIKEVAX during pregnancy is associated with an increased birth prevalence of adverse neonatal and infant outcomes, specifically neonatal encephalopathy, small for gestational age, respiratory distress in the newborn, and incidence of hospitalization due to infections including coronavirus disease 2019 (COVID-19).
* In women exposed to SPIKEVAX during pregnancy, to assess whether exposure to SPIKEVAX is associated with an increased prevalence of hypertensive disorders \[e.g., pre-eclampsia, eclampsia, and gestational hypertension\] gestational diabetes, and post-partum hemorrhage; and
* To assess whether exposure to SPIKEVAX during pregnancy is associated with an increased incidence of stillbirth, preterm birth, and medically attended spontaneous abortion.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- Female
- Target Recruitment
- 1192
- EOP within study period
- Continuous enrollment in a health plan contributing to the HealthCare Integrated Research Databaseâ„ (HIRD) database for at least 90 days prior to the estimated LMP.
- Exposure to any non-Moderna COVID-19 vaccines at any time prior to LMP and from LMP through the exposure ascertainment period for the outcome of interest. However, pregnant women exposed to other non-Moderna vaccines in addition to SPIKEVAX will be included in a sensitivity analysis.
- Instances where the outcome of a pregnancy is not documented (e.g., a prenatal care claim is followed by no further documentation of pregnancy, termination, or delivery where the participant remains enrolled in the health plan) may also be observed. The number of these possibly exposed pregnancies will be tabulated and described; however, they will not be included in the descriptive or comparative analyses.
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Number of Adverse Neonatal and Infant Outcomes Up to approximately 3 years Adverse neonatal and infant outcomes include neonatal encephalopathy, small for gestational age, respiratory distress in the newborn, or incidence of hospitalization due to infections including COVID-19.
Number of Stillbirths, Preterm Births, and Medically Attended Spontaneous Abortions Up to approximately 3 years Number of MCMs Up to approximately 3 years Number of Participants with Hypertensive Disorders Up to approximately 3 years Hypertensive disorders include pre-eclampsia, eclampsia, and gestational hypertension, gestational diabetes, or post-partum hemorrhage
- Secondary Outcome Measures
Name Time Method Healthcare Utilization: Number of Office Visits, Emergency Department Visits, and Hospitalizations Baseline Demographics: Age at LMP Baseline Demographics: Participant Socio-economic Status Baseline Demographics: Participant Region of Residence Baseline Demographics: Number of Overweight or Obese Participants Baseline Demographics: Duration of Health Plan Enrolment Prior to Pregnancy Baseline Demographics: Calendar Date of the Pregnancy Outcome Baseline Demographics: Participant Race and Ethnicity Baseline Healthcare Utilization: Number of Distinct Medications Used Baseline
Trial Locations
- Locations (1)
Carelon Research
đŸ‡ºđŸ‡¸Newton, Massachusetts, United States